Article citationsMore>>

LoRusso, P.M., Rudin, C.M., Reddy, J.C., Tibes, R., Weiss, G.J., Borad, M.J., et al. (2011) Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib [GDC-0449] in Patients with Refractory, Locally Advanced
or Metastatic Solid Tumors. Clinical Cancer Research, 17, 2502-2511. http://dx.doi.org/10.1158/1078
-0432.CCR-10-2745

has been cited by the following article:

• TITLE: Missing the Target?—Targeted Therapy in Small Cell Lung Cancer

  AUTHORS: Karin R. Purshouse

  KEYWORDS: Oncology, Small Cell Lung Cancer, Targeted Therapy, Drug Development

  JOURNAL NAME: Advances in Lung Cancer, Vol.3 No.3, August 22, 2014

  ABSTRACT: Small cell lung cancer [SCLC] is a devastating form of cancer, with most patients harbouring extensive disease at diagnosis and survival of less than 5% at five years. Progress in novel therapies has been limited. This specialist review explores current targeted therapy options and potential areas of development.